신경인지기능 장애로서 제2형 당뇨병 : 병태생리와 치료적 접근

키워드

참고문헌 (137)

1. International Diabetes Federation, "Diabetes Atlas" (2013), International Diabetes Federation
2. Chan JC, "Diabetes in Asia: epidemiology, risk factors, and pathophysiology", JAMA, 301, pp.2129~2140 (2009)
3. 김신곤, "특집", 우리나라 당뇨병의 현황, 2008, pp.51(9), 791~798[DOI]
4. Biessels GJ, "Increased cortical atrophy in patients with Alzheimer’s disease and type 2 diabetes mellitus", Journal of Neurology, Neurosurgery, and Psychiatry, 77, pp.304~307 (2006)
5. Lu FP, "Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis", PLoS One, 4, pp.e4144~ (2009)
6. Cukierman-Yaffe T, "Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors : the action to control cardiovascular risk in diabetes-memory in diabetes(ACCORDMIND)trial", Diabetes Care, 32, pp.221~226 (2009)
7. Brands AM, "The effects of type 1 diabetes on cognitive performance a meta-analysis", Diabetes Care, 28, pp.726~735 (2005)
8. Kodl CT, "Cognitive dysfunction and diabetes mellitus", Endocr Rev, 29, pp.494~511 (2008)
9. McCrimmon RJ, "Diabetes and cognitive dysfunction", Lancet, 379, pp.2291~2299 (2012)
10. Kahn SE, "The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes", Diabetologia, 46, pp.3~19 (2003)
11. de la Monte SM, "Alzheimer’s disease is type 3 diabetes-evidence reviewed", pp.1101~1113 (2008), J Diabetes Sci Technol
12. Shaw K, "‘Type 3 diabetes’: linking a brain insulin-resistant state with dementia and Alzheimer’s disease", Practical Diabetes (2013)
13. van Elderen SGC, "Progression of brain atrophy and cognitive decline in diabetes mellitus : a 3-year follow-up", Neurology, 75, pp.997~1002 (2010)
14. Patrone C, "Diabetes drugs and neurological disorders: new views and therapeutic possibilities", The Lancet Diabetes & Endocrinology (2013)
15. Craft S, "Insulin and neurodegenerative disease : shared and specific mechanisms", Lancet Neurol, 3, pp.169~178 (2004)
16. Hoyer S, "Glucose metabolism and insulin receptor signal transduction in Alzheimer disease", Eur J Pharmacol, 490, pp.115~125 (2004)
17. Skeberdis VA, "Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis", Proc Natl Acad Sci USA, 98, pp.3561~3566 (2001)
18. Zhao WQ, "Role of insulin and insulin receptor in learning and memory", Mol Cell Endocrinol, 177, pp.125~134 (2001)
19. Ma XH, "Muscarinic potentiation of GABA(A) receptor currents is gated by insulin signaling in the prefrontal cortex", J Neurosci, 23, pp.1159~1168 (2003)
20. Steen E, "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes?", J Alzheimers Dis, 7, pp.63~80 (2005)
21. Talbot K, "Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline", J Clin Invest, 122, pp.1316~1338 (2012)
22. Biessels GJ, "Risk of dementia in diabetes mellitus: a systematic review", Lancet Neurol, 5, pp.64~74 (2006)
23. Salkovic-Petrisic M, "Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway", J Neurochem, 96, pp.1005~1015 (2006)
24. Kernan WN, "Insulin resistance and risk for stroke", Neurology, 59, pp.809~815 (2002)
25. Rundek T, "Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study", Arch Neurol, 67, pp.1195~1200 (2010)
26. Brownlee M, "Biochemistry and molecular cell biology of diabetic complications", Nature, 414, pp.813~820 (2001)
27. Klein JP, "The brain in diabetes : molecular changes in neurons and their implications for endorgan damage", Lancet neurology, 2, pp.548~554 (2003)
28. Vitek MP, "Advanced glycation end products contribute to amyloidosis in Alzheimer disease", Proc Natl Acad Sci U S A, 91, pp.4766~4770 (1994)
29. Yamagishi S, "Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products(AGEs)may be a promising biomarker for early detection of Alzheimer’s disease", Med Hypotheses, 64, pp.1205~1207 (2005)
30. Yamamoto N, "Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes", Journal of Neurochemistry, 121, pp.619~628 (2012)
31. Baker LD, "Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes", Archives of Neurology, 68, pp.51~57 (2011)
32. Petersen KF, "Mitochondrial dysfunction in the elderly : possible role in insulin resistance", Science, 300, pp.1140~1142 (2003)
33. Correia SC, "Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer’s disease and diabetes interrelation", Brain Res, 1441, pp.64~78 (2012)
34. Rothman SM, "Excitotoxicity and the NMDA receptor--still lethal after eight years", Trends Neurosci, 18, pp.57~58 (1995)
35. Schinder AF, "Mitochondrial dysfunction is a primary event in glutamate neurotoxicity", J Neurosci, 16, pp.6125~6133 (1996)
36. Moreira PI, "Mitochondria as a therapeutic target in Alzheimer’s disease and diabetes", CNS Neurol Disord Drug Targets, 8, pp.492~511 (2009)
37. Moreira PI., "Alzheimer’s disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin", J Alzheimers Dis, 30(Suppl 2), pp.S199~S215 (2012)
38. Valastro B, "Up-regulation of glutamate receptors is associated with LTP defects in the early stages of diabetes mellitus", Diabetologia, 45, pp.642~650 (2002)
39. Trudeau F, "Hippocampal synaptic plasticity and glutamate receptor regulation : influences of diabetes mellitus", Eur J Pharmacol, 490, pp.177~186 (2004)
40. Akter K, "Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment?", Br J Clin Pharmacol, 71, pp.365~376 (2011)
41. Rasgon N, "Insulin resistance, affective disorders, and Alzheimer’s disease: review and hypothesis", The journals of gerontology Series A, Biological sciences and medical sciences, 59, pp.178~183 (2004)
42. Takeda S, "Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes", Proc Natl Acad Sci U S A, 107, pp.7036~7041 (2010)
43. Han W, "Linking type 2 diabetes and Alzheimer’s disease", Proc Natl Acad Sci U S A, 107, pp.6557~6558 (2010)
44. Schmidt R, "Magnetic resonance imaging of the brain in diabetes : the Cardiovascular Determinants of Dementia(CASCADE)Study", Diabetes, 53, pp.687~692 (2004)
45. Korf ESC, "Brain aging in very old men with type 2 diabetes : the Honolulu-Asia Aging Study", Diabetes Care, 29, pp.2268~2274 (2006)
46. Manschot SM, "Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes", Diabetes, 55, pp.1106~1113 (2006)
47. Novak V, "Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes", Diabetes Care, 29, pp.1529~1534 (2006)
48. Jongen C, "Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus", Diabetologia, 50, pp.1509~1516 (2007)
49. van Harten B, "Brain lesions on MRI in elderly patients with type 2 diabetes mellitus", European Neurology, 57, pp.70~74 (2007)
50. van Harten B, "Cognitive impairment and MRI correlates in the elderly patients with type 2 diabetes mellitus", Age and Ageing, 36, pp.164~170 (2007)
51. Kumar R, "Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64- year-old community sample", The American journal of geriatric psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 16, pp.989~998 (2008)
52. de Bresser J, "Progression of Cerebral Atrophy and White Matter Hyperintensities in Patients With Type 2 Diabetes", Diabetes Care, 33, pp.1309~1314 (2010)
53. Kamiyama K, "Potential hippocampal region atrophy in diabetes mellitus type 2 : a voxel-based morphometry VSRAD study", Japanese Journal of Radiology, 28, pp.266~272 (2010)
54. Yau PL, "Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus", Diabetologia, 53, pp.2298~2306 (2010)
55. Reijmer YD, "Accelerated cognitive decline in patients with type 2 diabetes : MRI correlates and risk factors", Diabetes, 2011, pp.27, 195~202
56. Brands AMA, "Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus : a comparative study", Dementia and geriatric cognitive disorders, 23, pp.343~350 (2007)
57. Bertram MY, "Quantifying the duration of prediabetes", Aust N Z J Public Health, 34, pp.311~314 (2010)
58. Tan ZS, "Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middleaged adults : the Framingham Offspring Study", Diabetes Care, 34, pp.1766~1770 (2011)
59. Willette AA, "Insulin Resistance, Brain Atrophy, and Cognitive Performance in Late Middle-Aged Adults", Diabetes care, 36, pp.443~449 (2013)
60. Kumar A, "Gray matter prefrontal changes in type 2 diabetes detected using MRI", J Magn Reson Imaging, 27, pp.14~19 (2008)
61. Bruehl H, "Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus", Brain Research, 1280, pp.186~194 (2009)
62. Lee JH, "Morphometric Changes in Lateral Ventricles of Patients with Recent-Onset Type 2 Diabetes Mellitus", PloS One, 8, pp.e60515~ (2013)
63. Kim JH, "Analysis of cerebral cortical thickness in patients with type 2 diabetes mellitus -a 6-month longitudinal follow-up study", 박사, pp.2014
64. Strachan MW, "The relationship between type 2 diabetes and dementia", Br Med Bull, 88, pp.131~146 (2008)
65. Squire LR, "The medial temporal lobe", Annu Rev Neurosci, 27, pp.279~306 (2004)
66. den Heijer T, "Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI", Diabetologia, 46, pp.1604~1610 (2003)
67. Gold SM, "Hippocampal damage and memory impairments as possible early brain complications of type 2diabetes", Diabetologia, 50, pp.711~719 (2007)
68. Brundel M, "Cerebral cortical thickness in patients with type 2 diabetes", Journal of the Neurological Sciences, 299, pp.126~130 (2010)
69. Volkow ND, "Reward, dopamine and the control of food intake: implications for obesity", Trends Cogn Sci, 15, pp.37~46 (2011)
70. McNay EC, "Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function", Curr Opin Pharmacol, 7, pp.628~632 (2007)
71. Massa F, "Alterations in the hippocampal endocannabinoid system in diet-induced obese mice", J Neurosci, 30, pp.6273~6281 (2010)
72. Mueller K, "Overweight and obesity are associated with neuronal injury in the human cerebellum and hippocampus in young adults: a combined MRI, serum marker and gene expression study", Transl Psychiatry, 2, pp.e200~ (2012)
73. Grillo CA, "Obesity", hyperleptinemic phenotype impairs structural and functional plasticity in the rat hippocampus, 2011, pp.105, 138~144
74. Moran C, "Brain Atrophy in Type 2 Diabetes: Regional distribution and influence on cognition", Diabetes Care (2013)
75. Braak H, "Neuropathological stageing of Alzheimer-related changes", Acta Neuropathol, 82, pp.239~259 (1991)
76. Thompson PM, "Dynamics of gray matter loss in Alzheimer’s disease", J Neurosci, 23, pp.994~1005 (2003)
77. Bartl J, "Alzheimer’s disease and type 2 diabetes: Two diseases, one common link?", The world journal of biological psychiatry: the Official Journal of the World Federation of Societies of Biological Psychiatry, 14, pp.233~240 (2013)
78. van den Berg E, "A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus", Diabetologia, 53, pp.58~65 (2010)
79. Reijmer YD, "Accelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors", Diabetes Metab Res Rev, 27, pp.195~202 (2011)
80. Biessels GJ, "Cognition and diabetes: a lifespan perspective", Lancet Neurol, 7, pp.184~190 (2008)
81. Ding J, "Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study", Diabetes, 59, pp.2883~2889 (2010)
82. Cabeza R, "Aging gracefully : compensatory brain activity in high-performing older adults", Neuroimage, 17, pp.1394~1402 (2002)
83. Buckner RL, "Memory and executive function in aging and AD : multiple factors that cause decline and reserve factors that compensate", Neuron, 44, pp.195~208 (2004)
84. Park DC, "The adaptive brain : aging and neurocognitive scaffolding", Annu Rev Psychol, 60, pp.173~196 (2009)
85. Erk S, "Evidence of neuronal compensation during episodic memory in subjective memory impairment", Arch Gen Psychiatry, 68, pp.845~852 (2011)
86. Burke SN, "Neural plasticity in the ageing brain", Nat Rev Neurosci, 7, pp.30~40 (2006)
87. Anderson RJ, "The prevalence of comorbid depression in adults with diabetes : a meta-analysis", Diabetes Care, 24, pp.1069~1078 (2001)
88. Ali S, "The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis", Diabetic Medicine, 23, pp.1165~1173 (2006)
89. Jorm AF, "Is depression a risk factor for dementia or cognitive decline? A review", Gerontology, 46, pp.219~227 (2000)
90. Ownby RL, "Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis", Arch Gen Psychiatry, 63, pp.530~538 (2006)
91. Katon WJ, "Comorbid depression is associated with an increased risk of dementia diagnosis in patients with diabetes: a prospective cohort study", J Gen Intern Med, 25, pp.423~429 (2010)
92. Katon W, "Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study", Arch Gen Psychiatry, 69, pp.410~417 (2012)
93. Sullivan MD, "Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial", JAMA Psychiatry, 70, pp.1041~1047 (2013)
94. Belmaker RH, "Major depressive disorder", N Engl J Med, 358, pp.55~68 (2008)
95. Knol MJ, "Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis", Diabetologia, 49, pp.837~845 (2006)
96. Golden SH, "Examining a bidirectional association between depressive symptoms and diabetes", JAMA, 299, pp.2751~2759 (2008)
97. Mezuk B, "Depression and Type 2 Diabetes Over the Lifespan: A meta-analysis", Diabetes Care, 31, pp.2383~2390 (2008)
98. Pan A, "Bidirectional association between depression and type 2 diabetes mellitus in women", Archives of Internal Medicine, 170, pp.1884~1891 (2010)
99. Roy T, "Epidemiology of depression and diabetes: a systematic review", J Affect Disord, 142(Suppl), pp.S8~S21 (2012)
100. Gupta A, "Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes", Neuropharmacology, 60, pp.910~920 (2011)
101. Correia S, "Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes", Med Chem, 4, pp.358~364 (2008)
102. El-Mir MY, "Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons", Mol Neurosci, 34, pp.77~87 (2008)
103. Kickstein E, "Biguanide metformin acts on tau phosphorylation via mTOR", protein phosphatase 2A(PP2A)signaling, 2010, pp.107, 21830~21835
104. Li J, "Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice", Pharmacol Biochem Behav, 101, pp.564~574 (2012)
105. Hwang IK, "Metformin normalizes type 2 diabetes-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus", Neurochem Res, 35, pp.645~650 (2010)
106. Wang J, "Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation", Cell Stem Cell, 11, pp.23~35 (2012)
107. Hsu CC, "Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin", J Alzheimers Dis, 24, pp.485~493 (2011)
108. Imfeld P, "Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population-based case-control study", J Am Geriatr Soc, 60, pp.916~921 (2012)
109. Chen Y, "Antidiabetic drug metformin(GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription", Proc Natl Acad Sci U S A, 106, pp.3907~3912 (2009)
110. de la Monte SM, "Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease", Drugs, 72, pp.49~66 (2012)
111. Yki-Jarvinen H, "Thiazolidinediones", N Engl J Med, 351, pp.1106~1118 (2004)
112. Retnakaran R, "Thiazolidinediones and clinical outcomes in type 2 diabetes", Lancet, 373, pp.2088~2090 (2009)
113. Kitamura Y, "Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains", Biochem Biophys Res Commun, 254, pp.582~586 (1999)
114. Berger J, "The mechanisms of action of PPARs", Annu Rev Med, 53, pp.409~435 (2002)
115. Watson GS, "The role of insulin resistance in the pathogenesis of Alzheimer’s disease : implications for treatment", CNS Drugs, 17, pp.27~45 (2003)
116. Pancani T, "Distinct modulation of voltagegated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons", J Neurochem, 109, pp.1800~1811 (2009)
117. Combs CK, "Inflammatory mechanisms in Alzheimer’s disease : inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists", J Neurosci, 20, pp.558~567 (2000)
118. Paddock ML, "MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone", Proc Natl Acad Sci U S A, 104, pp.14342~14347 (2007)
119. Kusminski CM, "MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity", Nat Med, 18, pp.1539~1549 (2012)
120. Sastre M, "Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase", J Neurosci, 23, pp.9796~9804 (2003)
121. Camacho IE, "Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide", J Neurosci, 24, pp.10908~10917 (2004)
122. Kaundal RK, "Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents", Drug News Perspect, 23, pp.241~256 (2010)
123. Sharma B, "Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats", Pharmacol Biochem Behav, 100, pp.320~329 (2011)
124. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial", Lancet, 366, pp.1279~1289 (2005)
125. Lincoff AM, "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus : a meta-analysis of randomized trials", JAMA, 298, pp.1180~1188 (2007)
126. Culman J, "Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia : a preclinical stroke trial", Exp Neurol, 238, pp.243~253 (2012)
127. Watson GS, "Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone : a preliminary study", Am J Geriatr Psychiatry, 13, pp.950~958 (2005)
128. Miller BW, "Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease", Ann Pharmacother, 45, pp.1416~1424 (2011)
129. Seaquist ER, "Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORDMIND", J Diabetes Complications, 27, pp.485~491 (2013)
130. Deacon CF, "Physiology of incretins in health and disease", Rev Diabet Stud, 8, pp.293~306 (2011)
131. Perfetti R, "The role of GLP-1 in the life and death of pancreatic beta cells", Horm Metab Res, 36, pp.804~810 (2004)
132. Cornu M, "GLP-1 protects β-cells against apoptosis by enhancing the activity of an IGF-2", IGF1-receptor autocrine loop, 2009, pp.1, 280~282
133. Gao H, "GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes", Endocrine, 32, pp.90~95 (2007)
134. During MJ, "Glucagon-like peptide-1 receptor is involved in learning and neuroprotection", Nat Med, 9, pp.1173~1179 (2003)
135. Isacson R, "The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test", Eur J Pharmacol, 650, pp.249~255 (2011)
136. Drucker DJ, "The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368, pp.1696~1705 (2006)
137. Deacon CF, "Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety", Expert Opin Pharmacother, 14, pp.2047~2058 (2013)

관련 논문AI추천